查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1926876

體外震波治療設備市場（按設備類型、應用和最終用戶分類）－2026-2032年全球預測

Extracorporeal Shock Wave Therapy Device Market by Device Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年體外震波治療設備市場價值為 2.272 億美元，預計到 2026 年將成長至 2.5916 億美元，複合年成長率為 14.41%，到 2032 年將達到 5.832 億美元。

關鍵市場統計數據
基準年 2025 2.272億美元
預計年份：2026年 2.5916億美元
預測年份 2032 5.832億美元
複合年成長率 (%) 14.41%

體外震波療法簡明概述：闡述臨床預期、商業性促進因素以及醫療保健領導者的決策要點

體外震波療法已從一種小眾治療方法發展成為一種用途廣泛的治療治療方法，可應用於包括美容、肌肉骨骼、心臟病學和泌尿系統在內的眾多臨床領域。近年來，臨床醫生和採購團隊日益認知到該技術作為一種非侵入性或微創替代傳統外科治療方法的潛力，從而帶動了醫院、專科診所和復健中心的需求。隨著臨床應用的普及，技術的改進和各種設備配置的出現，拓展了臨床醫生可選擇的治療方案，實現了更精準的能量傳輸和針對特定應用通訊協定的治療方案。

不斷變化的臨床適應症、技術進步和治療模式創新如何重塑衝擊波療法的競爭格局和推廣路徑

體外震波治療領域正經歷變革性的轉變，這得益於臨床、技術和治療模式創新的融合。在臨床方面，除傳統碎石和足底筋膜炎外，體外震波治療適應症的不斷拓展，推動了人們對美容應用、複雜整形外科修復以及某些心臟病病例的興趣。這種臨床應用的多樣化正在改變購買者對設備的評估方式，促使他們更加關注能夠支持多種適應症通訊協定的系統以及可減少多次資本投資的模組化配件。

為評估 2025 年生效的關稅對供應鏈和採購帶來的壓力，製造商和供應商被迫重新評估其採購、定價和證據策略。

計劃於2025年生效的針對特定醫療設備進口的關稅，使得供應鏈韌性和籌資策略的重要性日益凸顯。即使關稅僅針對零件或成品，製造商和經銷商在定價、採購和合約承諾方面也將面臨更大的複雜性。事實上，關稅將推高設備及配件的總到岸成本，進而影響預算緊張的醫院、專科診所和物理治療中心的採購週期。

細分市場分析洞察：設備架構、臨床適應症亞群和最終用戶操作需求如何交織，進而影響市場採納趨勢和產品策略

清楚了解器材和適應症的細分有助於產品設計、臨床開發和上市計劃。根據器械類型，聚焦式和放射式技術具有不同的臨床和商業性特性。聚焦式器械可輸送深層能量，通常優先用於需要靶向組織穿透的適應症。而放射式系統則將能量淺層分佈，常用於各種肌肉骨骼治療和美容通訊協定。按應用領域分類，市場涵蓋美容、心臟病學、整形外科和泌尿系統。在美容領域，減少橘皮組織和治療疤痕是熱門話題，這兩個都需要持續、可靠的美容效果、高效的工作流程和可預測的患者滿意度指標。在心臟病學領域，適應症包括心肌缺血和難治性心絞痛，由於需要可靠的臨床終點指標和整合到心臟護理路徑中，這兩項都存在較高的進入門檻。在整形外科領域，治療方法分為足底筋膜炎、肩迴旋肌損傷和網球肘，從業人員優先考慮器械的易用性、手術時間和可重複的臨床通訊協定。在泌尿系統領域，治療方法包括勃起功能障礙和腎結石治療，這些領域代表了具有不同監管要求和報銷預期的臨床群體。就最終用戶而言，醫療設備必須滿足醫院、整形外科診所和物理治療中心的實際營運需求。醫院需要能夠與複雜的診療流程整合並滿足嚴格的消毒和維護要求的設備，而整形外科診所則優先考慮快速的門診手術流程和醫生的偏好。物理治療中心需要經濟高效、易於操作的系統，以輔助保守治療並支持可衡量的功能改善。整合這些細分層面，可以揭示臨床需求、產品特性和購買行為之間的交集，從而突出製造商針對特定器械類型、適應症和最終用戶組合的優先發展機會，以最大限度地提高臨床影響和商業性吸引力。

區域監管差異、支付方趨勢和醫療服務模式將如何決定優先的打入市場策略和特定區域的證據需求？

區域特徵會影響監管時間表、支付方預期和臨床實踐模式，進而影響企業的市場推廣重點和資源分配。在美洲地區，門診手術量大，且醫療融資環境鼓勵在產品展現明確價值時進行創新，這些因素往往能夠推動臨床接受度。醫療服務模式從醫院向門診和診所的轉變，為注重效率和易用性的醫療設備創造了機遇，而當地的報銷政策也傾向於那些能夠切實降低後續成本的干涉措施。

為什麼臨床可靠性、卓越的服務和策略夥伴關係關係對於尋求在衝擊波治療領域獲得永續競爭優勢的公司至關重要

在體外震波治療領域，競爭優勢越來越取決於企業能否將臨床可靠性與營運關鍵的產品特性結合。領導企業透過整合取得專利的能量輸送系統、全面的培訓和服務項目以及基於價值的商業模式來降低採用者門檻，從而脫穎而出。與臨床意見領袖和早期應用中心建立策略夥伴關係仍然是建立循證基礎的核心，而循證基礎對於獲得更廣泛的支付方認可和臨床醫生支持至關重要。

為確保臨床應用和商業性成功，經營團隊可採取實際行動，透過數據利用、靈活的商業化以及遵守當地法規來實現這一目標。

產業領導者應優先採取切實可行的措施，將洞見轉化為可衡量的進展。首先，加快收集目標適應症和終端用戶環境中的真實世界臨床結果數據，以支持產品價值主張並與支付者溝通。高品質的註冊研究和前瞻性觀察性研究能夠彌合臨床試驗與常規實踐之間的差距，及時提供證據，從而在預算有限的環境下證明其可行性。其次，投資於模組化產品架構，使其能夠在單一平台上支援多種應用，從而減輕醫院和門診診所的採購負擔，同時最大限度地提高整個醫療團隊的利用率。

採用嚴謹的多源調查方法，結合臨床文獻、臨床醫師訪談、供應商分析和政策審查，得出可操作且檢驗的研究結果。

本研究採用多層次調查方法，結合一級資訊來源和二級資訊來源，結構嚴謹，旨在確保研究的廣度和深度。研究首先對同儕審查的臨床文獻、會議報告和監管文件進行全面回顧，按適應症梳理證據並確定關鍵績效指標。一手研究包括對醫院、整形外科診所和物理治療中心的臨床醫生進行結構化訪談，以了解最終用戶的偏好、操作流程和應用障礙。這些訪談為理解設備功能如何在實際臨床環境中轉化為實際應用價值提供了背景資訊。

匯聚的策略要務表明，產品設計、證據產生和商業性敏捷性的協調一致將決定長期實施的成功。

總之，體外震波療法正處於一個轉折點，臨床多樣化、設計創新和採購行為的轉變交匯融合，既帶來了巨大的機遇，也帶來了實際挑戰。能夠將卓越的技術與對終端使用者工作流程和區域監管現實的深刻理解相結合的機構，將更有機會取得成功。那些能夠建立可靠的真實世界數據、設計支援多種適應症的模組化平台並提供靈活商業條款的公司，將最有利於加速體外震波療法在醫院、整形外科診所和物理治療中心的推廣應用。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 體外震波治療設備市場（依設備類型分類）

  • 專注型
  • 徑向

第9章 體外震波治療設備市場（依應用領域分類）

  • 美麗
    • 減少橘皮組織
    • 疤痕治療
  • 心臟病學
    • 心肌缺血
    • 難治性心絞痛
  • 整形外科
    • 足底筋膜炎
    • 肩迴旋肌損傷
    • 網球肘
  • 泌尿系統
    • 勃起功能障礙
    • 腎結石治療

第10章 體外震波治療設備市場（依最終用戶分類）

  • 醫院
  • 整形外科診所
  • 物理治療中心

第11章 體外震波治療設備市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 體外震波治療設備市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 各國體外震波治療設備市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國體外震波治療設備市場

第15章 中國體外震波治療設備市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • BTL Industries
  • Dornier MedTech
  • EMS Electro Medical Systems
  • Guangzhou Longest Science & Technology
  • Gymna
  • Inceler Medikal
  • LIKAMED GmbH
  • MTS Medical
  • Richard Wolf GmbH
  • Storz Medical AG
  • Tissue Regeneration Technologies
  • Zimmer MedizinSysteme
Product Code: MRR-4F7A6D4FF34E

The Extracorporeal Shock Wave Therapy Device Market was valued at USD 227.20 million in 2025 and is projected to grow to USD 259.16 million in 2026, with a CAGR of 14.41%, reaching USD 583.20 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 227.20 million
Estimated Year [2026] USD 259.16 million
Forecast Year [2032] USD 583.20 million
CAGR (%) 14.41%

A concise orientation to extracorporeal shock wave therapy that outlines clinical promise, commercial drivers, and decision imperatives for healthcare leaders

Extracorporeal shock wave therapy has transitioned from a niche intervention to a clinically versatile modality applied across aesthetic, musculoskeletal, cardiology, and urology contexts. Over recent years, clinicians and procurement teams have increasingly recognized the technique's potential to offer non-invasive or minimally invasive alternatives to traditional surgical pathways, thereby creating demand among hospitals, specialty clinics, and rehabilitation centers. Alongside clinical adoption, engineering refinements and varying device architectures have broadened the therapeutic envelope available to practitioners, enabling more precise energy delivery and application-specific protocols.

Consequently, stakeholders must appreciate both the clinical evidence base and the commercial mechanics that enable or constrain adoption. Payers and health systems evaluate therapies through lenses of clinical efficacy, cost-effectiveness, and operational integration, while device manufacturers contend with design choices that influence capital expenditure, training burden, and consumable requirements. From a strategic perspective, understanding these intersecting pressures is essential to designing product roadmaps, clinical trials, and market access strategies that align with provider workflows and reimbursement realities.

Moving forward, the introduction frames the report's intent: to synthesize clinical trends, device differentiation, end-user requirements, and external policy drivers so that executives and clinical leaders can make informed decisions about investment, deployment, and partnership opportunities in extracorporeal shock wave therapy.

How evolving clinical indications, technological advances, and delivery model innovation are reshaping competitive dynamics and adoption pathways in shock wave therapy

The therapeutic landscape for extracorporeal shock wave therapy is experiencing transformative shifts driven by converging clinical, technological, and delivery-model innovations. Clinically, expanding evidence for indications beyond traditional stone fragmentation and plantar fasciitis has elevated interest in aesthetic applications, complex orthopedic repairs, and select cardiology use-cases. This clinical diversification changes how purchasers evaluate devices, pushing emphasis toward systems that can support multi-indication protocols and modular accessories that reduce the need for multiple capital purchases.

Technologically, advances in energy modulation, ergonomic probe design, and integrated imaging or guidance tools permit more targeted treatments and improved patient comfort. These advancements systematically lower barriers to adoption within outpatient and clinic settings by reducing procedure time and complication risk. At the same time, digital integration and data capture capabilities are enabling performance analytics and outcome tracking that payers increasingly demand to justify coverage and reimbursement.

From a delivery perspective, shifting care toward ambulatory surgery centers and specialized physiotherapy centers encourages manufacturers to design compact, portable systems suited to lower-acuity settings. In parallel, new commercial models, including flexible leasing and service bundle offerings, are realigning procurement decisions and enabling faster deployment. Taken together, these trends signify a landscape in which clinical versatility, ease of use, and data-driven outcomes increasingly determine competitive standing and long-term adoption trajectories.

Assessing the 2025 tariff-induced supply chain and procurement pressures that compel manufacturers and providers to rethink sourcing, pricing, and evidence strategies

Recent tariff measures announced for 2025 affecting certain medical device imports have created an environment in which supply chain resilience and procurement strategy require heightened attention. Even when tariffs apply to a subset of components or finished devices, manufacturers and distributors face increased complexity in pricing, sourcing, and contractual commitments. In practice, tariffs can amplify the total landed cost of devices and accessories, which in turn influences procurement cycles at hospitals, specialty clinics, and physiotherapy centers that operate under constrained capital budgets.

Manufacturers often respond by localizing production, reevaluating supplier relationships, or redesigning product architectures to substitute tariff-exposed components. Such adjustments can be strategically beneficial but demand upfront investment and a robust change management plan. Meanwhile, distributors and purchasing organizations have to reconcile longer lead times and potential cost variability with the need to maintain stable supply for clinical programs. Longer term, procurement teams may prioritize suppliers that demonstrate diversified manufacturing footprints or transparent cost pass-through mechanisms.

Moreover, tariffs can alter commercial conversations with payers and providers by increasing the emphasis on total cost of care and measurable outcomes. Stakeholders are likely to demand stronger evidence of clinical benefit and cost-offsets in light of higher device acquisition costs. Consequently, companies should prioritize post-market data collection and health economic analyses that demonstrate value in real-world settings. By doing so, organizations mitigate tariff-induced headwinds and position themselves as reliable partners for health systems navigating budgetary constraints.

Segment-driven insights revealing how device architecture, clinical indication subgroups, and end-user operational needs intersect to shape adoption and product strategy

A clear understanding of device and application segmentation informs product design, clinical development, and go-to-market planning. Based on device type, the clinical and commercial profiles diverge between Focused and Radial technologies; Focused devices concentrate energy at depth and are often prioritized for indications requiring targeted tissue penetration, whereas Radial systems disperse energy superficially and are commonly selected for diffuse musculoskeletal or aesthetic protocols. Based on application, the market spans Aesthetic, Cardiology, Orthopedic, and Urology uses. Within Aesthetic practice, attention centers on cellulite reduction and scar treatment, each demanding proof of consistent cosmetic outcomes, streamlined workflows, and predictable patient satisfaction metrics. Within Cardiology, indications include myocardial ischemia and refractory angina, both of which carry high barriers to adoption due to the need for robust clinical endpoints and integration with cardiac care pathways. Orthopedic applications break down into plantar fasciitis, rotator cuff injury, and tennis elbow, where practitioners emphasize device ergonomics, procedure time, and reproducible clinical protocols. Urology applications include erectile dysfunction and kidney stone treatment, representing distinct clinical communities with differing regulatory and reimbursement expectations. Based on end user, devices must address the operational realities of Hospitals, Orthopedic Clinics, and Physiotherapy Centers. Hospitals demand devices that integrate with complex care pathways and meet stringent sterilization and service requirements, while orthopedic clinics prioritize devices that enable rapid throughput of ambulatory procedures and strong physician preference. Physiotherapy centers look for cost-effective, easy-to-operate systems that augment conservative care and support measurable functional improvements. Integrating these segmentation layers reveals where clinical demand, product features, and purchasing behavior intersect, and it highlights prioritization opportunities for manufacturers targeting specific combinations of device type, application, and end user to maximize clinical impact and commercial traction.

How nuanced regional differences in regulation, payer dynamics, and care delivery models determine prioritized market entry strategies and localized evidence needs

Regional dynamics influence regulatory timelines, payer expectations, and clinical practice patterns, thereby shaping how companies prioritize market entry and resource allocation. In the Americas, clinical acceptance is often driven by strong procedural volumes in outpatient centers and a healthcare financing environment that can support innovation when clear value is demonstrated. Transitioning from hospital-centric care to ambulatory and clinic-based treatment settings has created opportunities for devices designed for throughput and ease of use, and local reimbursement policies favor interventions with tangible reductions in downstream costs.

Across Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable payer models create a need for regionally tailored evidence packages and commercial approaches. In some European markets, centralized health technology assessment mechanisms require robust comparative-effectiveness data, while other jurisdictions emphasize cost containment and clinician-led adoption. Middle Eastern and African markets may prioritize different product attributes, such as ease of maintenance and total cost of ownership, given varying infrastructure constraints.

In the Asia-Pacific region, rapid expansion of private specialty clinics and increasing investment in non-invasive therapeutic modalities fuel interest in shock wave devices. Regulatory regimes are evolving to balance innovation and safety, and local manufacturing or distribution partnerships are frequently advantageous. Additionally, cultural and practice-pattern differences influence which applications gain early traction, underscoring the need for localized clinical studies and culturally attuned marketing strategies. Across all regions, a nuanced combination of regulatory preparedness, evidence generation, and channel partnerships will determine success.

Why clinical credibility, service excellence, and strategic partnerships are decisive for firms seeking durable competitive advantage in shock wave therapy

Competitive positioning within the extracorporeal shock wave therapy space increasingly depends on a company's ability to combine clinical credibility with operationally relevant product features. Leaders differentiate through a mix of patented energy delivery systems, comprehensive training and service programs, and value-based commercial models that reduce friction for adopters. Strategic partnerships with clinical opinion leaders and early adoption sites remain central to building the evidence base required for broader payer acceptance and clinician endorsement.

Beyond core technology, after-sales support and clinical education are decisive factors for many purchasers, particularly in high-volume hospitals and specialty clinics. Companies that offer structured training curricula, outcome-tracking platforms, and field service agreements reduce perceived risk and accelerate the transition from trial use to routine clinical deployment. In parallel, organizations investing in digital tools for documentation and remote monitoring are better positioned to capture real-world outcomes that inform reimbursement discussions and continuous product improvement.

Mergers and alliances continue to reshape competitive dynamics as larger medical device companies seek to add complementary energy-based therapies to their portfolios and specialist manufacturers pursue scale or distribution reach. For smaller innovators, focused indication strategies and nimble regulatory approaches can create pathways to differentiation. Ultimately, the combination of technology robustness, service excellence, and evidence generation capacity determines whether a firm secures meaningful clinical penetration and long-term revenue stability.

Practical actions for executives to secure clinical adoption and commercial traction through data, flexible commercialization, and localized regulatory alignment

Industry leaders should prioritize a set of actionable moves that translate insight into measurable progress. First, accelerate collection of real-world outcome data across targeted indications and end-user settings to substantiate value claims and support payer conversations. High-quality registries and prospective observational studies can bridge gaps between clinical trials and everyday practice, offering timely evidence to justify adoption in budget-constrained environments. Second, invest in modular product architectures that enable a single platform to address multiple applications, thereby reducing the procurement burden on hospitals and outpatient centers while maximizing utilization across care teams.

Third, reconfigure commercial models to align with provider cash-flow realities by offering flexible procurement options such as leasing, pay-per-use, or bundled service agreements. Such models can lower upfront barriers and encourage broader device trialing. Fourth, strengthen regional regulatory and distribution strategies by cultivating local partnerships that expedite market entry and accommodate jurisdictional evidence requirements. Fifth, design education and support programs that reduce clinical variability and ensure consistent procedural quality; this includes training for physicians, technicians, and administrative staff along with standardized outcome measurement protocols.

Implementing these recommendations requires cross-functional coordination across clinical affairs, regulatory, commercial, and supply chain teams. By aligning organizational incentives around clear clinical outcomes and provider-centric value propositions, companies can accelerate adoption while mitigating external pressures such as tariff volatility and evolving payer expectations.

A rigorous multi-source methodology blending clinical literature, clinician interviews, vendor analysis, and policy review to produce actionable, validated insights

The research employed a multi-tiered methodology combining primary and secondary sources, structured to ensure both breadth and depth of insight. The approach began with a comprehensive review of peer-reviewed clinical literature, conference proceedings, and regulatory filings to map indication-specific evidence and identify key performance metrics. Primary research included structured interviews with clinicians across hospitals, orthopedic clinics, and physiotherapy centers to capture end-user preferences, procedural workflows, and adoption barriers. These interviews provided context for how device features translate into operational value in real-world settings.

Complementing clinical and end-user inputs, vendor landscape analysis examined product portfolios, service offerings, and go-to-market approaches to understand competitive differentiation. Supply chain and policy analyses evaluated the implications of component sourcing, manufacturing footprints, and tariff exposure. Throughout the process, triangulation techniques were applied to reconcile disparate inputs and validate conclusions, ensuring that recommendations reflect convergent evidence rather than isolated data points.

Finally, sensitivity checks and peer reviews with external clinical advisors helped refine interpretations and prioritize insights that are most actionable for commercial and clinical leaders. This methodology produces a balanced synthesis of academic rigor and practical relevance, equipping stakeholders to make informed decisions about product development, market entry, and clinical strategy.

Synthesis of strategic imperatives showing how aligned product design, evidence generation, and commercial agility will determine long-term adoption success

In sum, extracorporeal shock wave therapy stands at an inflection point where clinical diversification, design innovation, and shifting procurement behaviors converge to create meaningful opportunities and practical challenges. Success will favor organizations that pair technical excellence with a pragmatic understanding of end-user workflows and regional regulatory realities. Companies that build credible real-world evidence, design modular platforms suited to multiple indications, and offer flexible commercial terms will be best positioned to accelerate adoption across hospitals, orthopedic clinics, and physiotherapy centers.

At the same time, external pressures such as tariff changes and evolving payer expectations necessitate proactive supply chain planning and stronger health economics evidence. Decision-makers must therefore integrate clinical development, manufacturing strategy, and commercial planning into a cohesive roadmap to mitigate risk and capture emerging demand. By aligning product features with operational needs and investing in outcomes measurement, stakeholders can demonstrate value to clinicians, patients, and payers alike.

Ultimately, the pathway to broader integration of shock wave therapy into standard care rests on translating clinical promise into reproducible, documented benefit within everyday practice. Organizations that achieve this translation will secure meaningful clinical and commercial returns while improving patient access to less invasive therapeutic options.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Extracorporeal Shock Wave Therapy Device Market, by Device Type

  • 8.1. Focused
  • 8.2. Radial

9. Extracorporeal Shock Wave Therapy Device Market, by Application

  • 9.1. Aesthetic
    • 9.1.1. Cellulite Reduction
    • 9.1.2. Scar Treatment
  • 9.2. Cardiology
    • 9.2.1. Myocardial Ischemia
    • 9.2.2. Refractory Angina
  • 9.3. Orthopedic
    • 9.3.1. Plantar Fasciitis
    • 9.3.2. Rotator Cuff Injury
    • 9.3.3. Tennis Elbow
  • 9.4. Urology
    • 9.4.1. Erectile Dysfunction
    • 9.4.2. Kidney Stone Treatment

10. Extracorporeal Shock Wave Therapy Device Market, by End User

  • 10.1. Hospital
  • 10.2. Orthopedic Clinic
  • 10.3. Physiotherapy Center

11. Extracorporeal Shock Wave Therapy Device Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Extracorporeal Shock Wave Therapy Device Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Extracorporeal Shock Wave Therapy Device Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Extracorporeal Shock Wave Therapy Device Market

15. China Extracorporeal Shock Wave Therapy Device Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. BTL Industries
  • 16.6. Dornier MedTech
  • 16.7. EMS Electro Medical Systems
  • 16.8. Guangzhou Longest Science & Technology
  • 16.9. Gymna
  • 16.10. Inceler Medikal
  • 16.11. LIKAMED GmbH
  • 16.12. MTS Medical
  • 16.13. Richard Wolf GmbH
  • 16.14. Storz Medical AG
  • 16.15. Tissue Regeneration Technologies
  • 16.16. Zimmer MedizinSysteme

LIST OF FIGURES

  • FIGURE 1. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY FOCUSED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY FOCUSED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY FOCUSED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY RADIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY RADIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY RADIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CELLULITE REDUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CELLULITE REDUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CELLULITE REDUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY SCAR TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY SCAR TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY SCAR TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY MYOCARDIAL ISCHEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY MYOCARDIAL ISCHEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY MYOCARDIAL ISCHEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY REFRACTORY ANGINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY REFRACTORY ANGINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY REFRACTORY ANGINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY PLANTAR FASCIITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY PLANTAR FASCIITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY PLANTAR FASCIITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ROTATOR CUFF INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ROTATOR CUFF INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ROTATOR CUFF INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY TENNIS ELBOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY TENNIS ELBOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY TENNIS ELBOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ERECTILE DYSFUNCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ERECTILE DYSFUNCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ERECTILE DYSFUNCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY KIDNEY STONE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY KIDNEY STONE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY KIDNEY STONE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY PHYSIOTHERAPY CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY PHYSIOTHERAPY CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY PHYSIOTHERAPY CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GCC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. GCC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. GCC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 141. GCC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. GCC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 143. GCC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. GCC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. G7 EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. G7 EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. G7 EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 165. G7 EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. G7 EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 167. G7 EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. G7 EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. NATO EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. NATO EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. NATO EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 173. NATO EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. NATO EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 175. NATO EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. NATO EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)